S
Surginex
Innovative biotech solutions leveraging AI and CRISPR-Cas9 for advanced genetic research and therapeutic development
About Surginex
Surginex operates in the biotechnology sector, focusing on advanced genetic research and therapeutic development. The company leverages cutting-edge technologies such as Artificial Intelligence (AI) and CRISPR-Cas9 to innovate in the field of genetic engineering. Surginex serves a diverse clientele, including academic institutions, pharmaceutical companies, and research organizations. The business model revolves around providing specialized research services and developing proprietary therapeutic solutions. Revenue is generated through service contracts, licensing agreements, and partnerships with other biotech firms. Surginex's market is highly specialized, targeting sectors that require advanced genetic manipulation and data analysis capabilities. The company is led by a team of experts with extensive experience in AI and genetic research, ensuring a strong foundation for innovation and growth.
Source: Dealroom company dataAt a glance
- Founded
- 2015
- Headquarters
- Seoul, South Korea
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
- PCPosco Capital
- LILSK Investment
- KIKiwoom Investment
Laguna Investment
Hana Ventures
Partners Investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Surginex on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Surginex on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.